Platform Partnerships Frontier's discovery platform blends chemoproteomics, covalent drug discovery, and AI, with licensing activity such as FMC-220 to LG Chem and upcoming FMC-242. This mix signals opportunities for licensing, co-development, or platform as a service collaborations to access cutting edge science for difficult to drug oncology targets.

Undruggable Targets Frontier specializes in disease causing proteins previously considered undruggable, including KRAS G12C and p53 Y220C, using chemoproteomics and covalent chemistry. The focus creates openings for partners to expand into new undruggable targets via joint discovery programs or licensing arrangements that accelerate asset timelines.

AI Platform The AI powered Frontier Platform accelerates target identification and molecule design, supported by a modern cloud stack such as FastAPI and AWS EKS. These capabilities open doors for enterprise access, data licensing, or white label collaborations with biotech and pharma clients seeking faster R and D cycles.

Oncology Focus With a pipeline centered on cancer drivers like KRAS G12C and p53 Y220C, Frontier offers opportunities for collaborators to augment oncology portfolios through shared preclinical and discovery work. The LG Chem licensing example demonstrates market interest in external partnerships to advance oncology programs.

Growth Signals Recent leadership appointment of Andrew Krivoshik as chief medical officer in August 2025, multiple preclinical data disclosures, and licensing activity, along with revenue and funding signals, indicate readiness for external collaborations and late preclinical to early clinical co development deals.